Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
Status:
Withdrawn
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate anatomical and functional effect of combination
therapy of Squalamine Lactate Ophthalmic Solution, 0.2% administered twice daily with monthly
ranibizumab intravitreal injections in patients with choroidal neovascularization due to AMD.